Macrogenics (MGNX) Free Cash Flow (2012 - 2026)
Macrogenics (MGNX) posted quarterly Free Cash Flow of -$36.1 million for Q1 2026, up 23.61% year-over-year from -$29.2 million in Q1 2025, and down 183.97% quarter-over-quarter from $43.0 million in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) Free Cash Flow (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Free Cash Flow for 15 consecutive years, with -$36.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 23.61% year-over-year to -$36.1 million; the TTM figure through Mar 2026 stood at -$69.9 million (up 4.76% YoY), while the FY2025 annual figure was -$81.1 million, down 12.51% from the prior year.
- Free Cash Flow fell to -$36.1 million in Q1 2026 per MGNX's latest filing, from $43.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $57.1 million in Q3 2024 and bottomed at -$59.1 million in Q1 2022.
- Historically, Free Cash Flow has averaged -$21.1 million across 5 years, with a median of -$35.7 million in 2023.
- On a YoY basis, Free Cash Flow climbed as much as 259.78% in 2024 and fell as far as 1631.68% in 2024.
- Macrogenics' Free Cash Flow stood at $28.9 million in 2022, then slumped by 194.71% to -$27.4 million in 2023, then sank by 42.44% to -$39.0 million in 2024, then soared by 210.11% to $43.0 million in 2025, then slumped by 183.97% to -$36.1 million in 2026.
- Business Quant data shows MGNX's Free Cash Flow at -$36.1 million in Q1 2026, $43.0 million in Q4 2025, and -$30.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | -41.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -41.55 Mn |
| Mar 31, 2026 | -36.16 Mn |
| Dec 31, 2025 | 42.78 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Jun 30, 2025 | -47.70 Mn |
| Mar 31, 2025 | -47.42 Mn |
| Dec 31, 2024 | -39.03 Mn |
| Sep 30, 2024 | 59.57 Mn |
| Jun 30, 2024 | -45.52 Mn |
| Mar 31, 2024 | -47.10 Mn |
| Dec 31, 2023 | -28.66 Mn |
| Sep 30, 2023 | -35.75 Mn |
| Jun 30, 2023 | -2.38 Mn |
| Mar 31, 2023 | -13.19 Mn |
| Dec 31, 2022 | 28.93 Mn |
| Sep 30, 2022 | -10.23 Mn |
| Jun 30, 2022 | -50.17 Mn |
| Mar 31, 2022 | -59.11 Mn |
| Dec 31, 2021 | -55.68 Mn |
| Sep 30, 2021 | -16.93 Mn |